Trial Profile

An Open-Label, Relative Bioavailability Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ropinirole Implants in Patients With Parkinson's Disease Switched From Oral Immediate-Release Ropinirole While on L-Dopa

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 09 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ropinirole (Primary) ; Ropinirole (Primary)
Indications Parkinson's disease
Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
Sponsors Titan Pharmaceuticals

04 Feb 2020 Status changed from suspended to discontinued.
19 Apr 2019 Planned End Date changed from 1 Dec 2018 to 1 Jul 2020.
19 Apr 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jul 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com